Stem­line comes clean on pa­tient death, but ques­tions linger; Life sci­ences fund launch­es with €100M

• Stem­line $STML has been forced to ad­mit that it re­ceived a re­port that one of the pa­tients in its piv­otal study of SL-401 for blas­tic plas­ma­cy­toid den­drit­ic cell neo­plasm (BPD­CN) died af­ter de­vel­op­ing cap­il­lary leak syn­drome, a con­di­tion that has al­ready been linked to the drug. That ad­mis­sion fol­lowed a sto­ry from TheStreet’s Adam Feuer­stein, who re­vealed the pa­tient’s death for the first time. The big prob­lem here is the tim­ing. The death no­tice came on Jan­u­ary 18, a day ahead of a $45 mil­lion of­fer­ing, which failed to dis­close the is­sue. The biotech’s shares have been ripped and an­a­lysts are won­der­ing if the com­pa­ny can re­gain share­hold­ers’ con­fi­dence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER